Healthcare IT and Services

Karo Bio

December 2010

TRANSAKTION

A rights share issue providing SEK 300 million for funding a phase III trial of the Company´s main development project, eprotirome.

FÖRETAGET

Karo Bio is a Swedish pharmaceutical company which since 1986 has focused on the nuclear receptor area generating an innovative project pipeline. The leading compound eprotirome enters clinical phase III development as a dyslipidemia drug with strong phase II data and a unique mechanism of action.

AKTIEÄGARE

A public company listed on Nasdaq Small Cap OMX.

Prev Next View all transactions
Cookies

This website is using cookiesfor statistics and user experience

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.